Sm. Dresner et al., Prognostic significance of peri-operative blood transfusion following radical resection for oesophageal carcinoma, EUR J SUR O, 26(5), 2000, pp. 492-497
Introduction: Peri-operative allogeneic blood transfusion may exert an immu
nomodulatory effect and has been associated with early recurrence and decre
ased survival following resection for several gastro-intestinal malignancie
s. The aim of this study was to evaluate the prognostic influence of transf
usion requirements following radical oesophagectomy for cancer.
Methods: A consecutive series of 235 patients undergoing subtotal oesophage
ctomy with two-field lymphadenectomy in a single centre from April 1990 to
June 1999 were studied.
Results: The median age was 64 years (30-79) with a male to female ratio of
3:1. The predominant histological subtype was adenocarcinoma (n=154) compa
red to squamous carcinoma (n=81). To avoid the influence of surgical compli
cations data were excluded from the 5.5% of patients suffering in-hospital
mortality. In the remaining patients, median blood loss was 900 mi (200-550
0) with 46% (103/222) requiring transfusion (median 3 units, range 2-21). M
edian survival of non-transfused patients was 36 months compared to only 19
months for those receiving transfusion (log-rank=4.44; 1 df, P=0.0352). No
n-transfused patients had significantly higher 2 and 5-year survival rates
of 62% and 41% respectively in contrast to only 40% and 25% in those receiv
ing blood transfusion. Even after stratification of results according to di
sease stage or the presence of major complications, survival was significan
tly worse in those receiving transfusion. Multivariate analysis demonstrate
d that in addition to nodal status, >4 units transfusion was an independent
prognostic indicator.
Conclusion: Post-operative transfusion is associated with a significantly w
orse prognosis following radical oesophagectomy. Meticulous haemostasis and
avoidance of unnecessary transfusion may prove oncologically beneficial. (
C) 2000 Harcourt Publishers Ltd.